Johnson & Johnson Aktie
| 152,72USD | -2,07USD | -1,34% |
WKN: 853260 / ISIN: US4781601046
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 99,88 |
| The Vanguard Group, Inc. | 9,53 |
| Vanguard Group, Inc. (Subfiler) | 9,15 |
| State Street Corp. | 5,58 |
| SSgA Funds Management, Inc. | 5,52 |
| Vanguard Total Stock Market ETF | 3,17 |
| BlackRock Fund Advisors | 3,11 |
| Vanguard 500 Index Fund | 2,62 |
| Geode Capital Management LLC | 2,33 |
| BlackRock Institutional Trust Co. NA | 2,21 |
| State Farm Investment Management Corp. | 1,32 |
| Fidelity 500 Index Fund | 1,23 |
| SPDR S&P 500 ETF Trust | 1,21 |
| Norges Bank (13F) | 1,21 |
| iShares Core S&P 500 ETF | 1,11 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 132 200 | 134 500 | 141 700 | 152 700 | 131 900 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,62 | 0,61 | 0,66 | 0,62 | 0,65 |
Bilanz (in Mio. USD) - Aktiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 45 274 | 51 237 | 60 979 | 55 294 | 53 495 |
| Summe Anlagevermögen | 112 454 | 123 657 | 121 039 | 132 084 | 114 063 |
| Summe Aktiva | 157 728 | 174 894 | 182 018 | 187 378 | 167 558 |
Bilanz (in Mio. USD) - Passiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 28 681 | 36 366 | 34 751 | 40 959 | 30 432 |
| Summe Fremdkapital | 98 257 | 111 616 | 107 995 | 110 574 | 98 784 |
| Summe Eigenkapital | 59 471 | 63 278 | 74 023 | 76 804 | 68 774 |
| Summe Passiva | 157 728 | 174 894 | 182 018 | 187 378 | 167 558 |
Adresse
| One Johnson & Johnson Plaza, 08933 New Brunswick | |
| Telefon | +1 (732) 524-0400 |
| Internet | http://www.jnj.com |
Management
|
Anne M. Mulcahy
Independent Director |
|
Caroline Tillett
Global Head-Consumer Health |
|
Darius Adamczyk
Independent Director |
|
Elizabeth Forminard
Executive Vice President & General Counsel |
|
Eugene A. Woods
Independent Director |
|
George Davy
Global HR Director |
|
Hubert Joly
Independent Director |
|
James D. Swanson
Chief Information Officer & Executive VP |
|
Jennifer A. Doudna
Independent Director |
|
Jennifer L. Taubert
EVP & Worldwide Chairman-Innovative Medicine |
|
Jessica Moore
Vice President-Investor Relations |
|
Joaquin Duato
Chairman & Chief Executive Officer |
|
John C. Reed
Executive Vice President-Innovative Medicine |
|
Jonathan Sheh
Director-Workplace Experience |
|
Joseph J. Wolk
Chief Financial Officer & Executive Vice President |
|
Juliana Clawson
Head-Global Quality & Compliance |
|
Kathryn E. Wengel
Chief Technical Operations & Risk Officer |
|
Kristen Blair Mulholland
Chief Human Resources Officer & Executive VP |
|
Lisa Paley
Vice President-US Sales |
|
Marc Larkins
Secretary & Vice President-Governance |
|
Marillyn A. Hewson
Lead Independent Director |
|
Mark Alan Weinberger
Independent Director |
|
Mark B. McClellan
Independent Director |
|
Mary C. Beckerle
Independent Director |
|
Meredith Stevens
Vice President |
|
Michael Bzdak
Global Dir-Employee Engagement-Global Cmnty Impact |
|
Nadja Y. West
Independent Director |
|
Neil Ackerman
Head-Innovation, Global Supply & Transformation |
|
Paul Ruh
Chief Financial Officer-Consumer Health |
|
Paula A. Johnson
Independent Director |
|
Robert J. Decker
Chief Accounting Officer & Controller |
|
Ronald A. Kapusta
Chief Accounting Officer & Controller |
|
Thomas J. Spellman
Secretary |
|
Timothy Schmid
Executive Vice President & Chairman-Worldwide |
|
William E. Cohn
Vice President-Medical Devices |
|
William N. Hait
Chief External Innovation & Executive VP-Medical |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
